The antiarrhythmic properties of amiodarone were recognised soon after its introduction as an antianginal drug. Early experience showed the drug to be effective in children with cardiac arrhythmias'; amiodarone resulted in either complete control (60%) or clinical improvement (330/').1 The oral dosage and plasma concentrations of amiodarone associated with arrhythmia suppression in children have not been previously reported.
The unwanted effects experienced by adults receiving treatment with amiodarone2 3 have been reported to occur less commonly in children. In a study by Coumel and Eight children needed digoxin in addition to amiodarone and one needed amiodarone, digoxin, and verapamil to suppress arrhythmia.
Intravenous amiodarone had not been used before in the two children in whom it was ineffective. The plasma concentrations of amiodarone and desethylamiodarone and the dosage used were not Amiodarone in children 279 Table 2 significantly different from those that suppressed arrhythmia. These two children had paroxysmal orthodromic reentry atrioventricular tachycardias that were resistant to conventional treatment. Electrophysiological testing demonstrated wide atrial initiation zones for these tachycardias that have now been controlled by a combination of pre-excitation pacing7 and antiarrhythmic drugs (/ blockade was used in one and verapamil in the other). Table 2 shows the dosages given and the plasma concentrations of amiodarone and desethylamiodarone when arrhythmia suppression was achieved and on maintenance therapy. The dosage of oral amiodarone associated with initial arrhythmia suppression ranged from 217 to 34mg/kg per day (mean 10 2 mg/kg/day). The maintenance doses required (mean 6 0 mg/kg/day) were significantly lower than the dosages used initially. Higher doses (mean 15-3 mg/kg/day) were required to attain arrhythmia suppression in infants under one year of age than in older children (mean 7-2 mg/kg/day) (p < 0 05); the difference in dosage between the two age groups was not significant when the dosage was calculated in terms of mg/M2. Similarly, infants required higher doses during maintenance therapy when this was calculated according to body weight but not if the doses were calculated according to surface area.
The plasma concentration of amiodarone associated with initial arrhythmia suppression (mean 0-98mg/1) was not significantly different from that achieved during maintenance treatment (mean 0 84mg/l), though the maintenance doses were lower than the doses used initially. The plasma concentration of amiodarone was related to the dose given, both in the initial phase (correlation coefficient r = +0 73, p < 0-001) and during maintenance treatment (correlation coefficient r = +0-62, p < 0 001 in nine of 14 children who had slit lamp examination (aged seven to 14 years), and in one of these dense aggregated deposits (fig 2) persisted for 12 months after treatment was discontinued because of grey pigmentation. One child complained of gritty eyes but no ophthalmological abnormality could be detected; the symptoms were so severe that treatment was discontinued and this symptom disappeared. Treatment was stopped because of unwanted effects in a total of five patients. The weight of a child is often used to calculate the dose (mg/kg/day) and this may lead to an ineffective dose of amiodarone being prescribed for infants. The plasma concentration of amiodarone associated with arrhythmia suppression was similar in infants and older children, but the dose required to achieve arrhythmia suppression when calculated according to weight (mg/kg/day) was higher in the infant group than in those aged over one year. Dosages calculated on the basis of surface area were not significantly higher in the infant group. The plasma concentration of amiodarone associated with arrhythmia suppression was similar in the infant and older age groups but the plasma concentration of desethylamiodarone associated with arrhythmia suppression was significantly lower in the infant group; this may have been the result of a more rapid excretion or reduced production of the metabolite in infants. In children, as in adults, there was a correlation between the dose and the plasma concentration of amiodarone.'0 In contrast there was no such correlation between the dose of amiodarone and the plasma concentration of the metabolite desethylamiodarone.
Amiodarone can be given either intravenously or orally; unwanted cardiovascular effects are more commonly reported after intravenous administration. In all age groups potentially serious cardiovascular complications, such as atrioventricular block, hypotension, or shock, may occur after intravenous amiodarone. " In contrast the oral administration of amiodarone in children has been reported to be relatively free from adverse effects, even in those with cardiomegaly and congestive heart failure. ' We report a high incidence of skin photosensitivity, grey pigmentation, and corneal deposits in children on amiodarone; this was similar to that found in adults.2 3 Unwanted effects were more common than had been previously reported in this age group, but group analysis showed that the occurrence of the unwanted effects was unrelated to the dose, duration of treatment, or plasma concentration of amiodarone. Few major adverse effects thought to be related to amiodarone dose were encountered, other 284 Bucknall, Keeton, Curry, Tynan, Sutherland, Holt than skin pigmentation and biochemical hepatic dysfunction (there were no cases involving pulmonary complications, clinical hepatic dysfunction, neuropathy, or myopathy). Plasma concentrations of amiodarone in the two children with grey pigmentation and the four children with biochemical hepatic dysfunction were high, and those with pigmentation and sleep disturbance were receiving higher maintenance doses of amiodarone than those who were unaffected.
We conclude that amiodarone is an effective antiarrhythmic drug in childhood but that its use should be reserved for those with resistant life threatening arrhythmias. Particular care should be taken with infants for whom a higher weight related oral dose is required to achieve arrhythmia suppression. We suggest that oral doses should be calculated on the basis of surface area. Arrhythmia control is associated with a wide range of plasma concentrations of amiodarone and more data are needed to investigate the clinical value of plasma measurements as a guide to avoiding serious adverse effects.
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